Moderna, Inc.

Good morning. My name is Kevin, and welcome to Moderna's first quarter 2022 earnings call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded. At this time, I'd like to turn the call over to Labina Talukdar, Head of Innovations at Moderna. Please proceed.

Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's first quarter 2022 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the Investor section of our website. On today's call are Stephon Boncel, our Chief Executive Officer, David Moline, our Chief Financial Officer, Stephen Hogue, our President, and Paul Burton, our Chief Medical Officer. Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see slide two of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. I will now turn the call over to Stephane.

Thank you, Lavinia. Good morning or good afternoon, everyone. Welcome to our Q1 2021-82 conference call. Today, I will start by a quick business review of a quarter before Paul walks you through an update on SPACBAC's real-world evidence, and then Stephen reviews our clinical programs. David will then present the key financials, and I will then come back to conclude before we take your questions. I am happy to share that the team delivered strong financial results this quarter, and revenues of $6.1 billion, GAAP net income of $3.7 billion, and GAAP diluted EPS of $8.58. We ended Q1 with a cash balance of $19.3 billion. For our share buyback program, we continue to retire shares in Q1 like we already did in Q4. David will share some numbers on share count in a few minutes. For 2022, we are reiterating $21 billion in signed advanced purchase agreements. We have previously shared market share increases seen in the OECD countries with Spivax, when supply was no longer limited, and when real-world publications highlighted differentiating data amongst the marketed vaccine. I'm happy to share that our market share has increased or stayed consistent across OECD countries. While a subset of our team is focused on delivering on the 21 billion signed APAs for the fiscal year 2022, another subset of our team is focused on preparing the next wave of product launches. We have a flu vaccine candidate, MRD-1010, planned to start a phase 3 study in Q2 in the southern hemisphere. Moderna will have very soon four vaccine candidates in phase 3. An Omicron-containing virulent COVID booster, a flu booster, an RSV booster, and a CMV-impromptu-series vaccine. Starting with our Omicron-containing viral COVID booster, mRNA-1273.214, we could see up to three respiratory vaccine launches from the fall of 2022 over the next two to three years. We believe each of these four vaccine candidates in Phase 3 could have multi-billion-dollar annual peak sales. And because they all use the exact same mRNA technology as our approved vaccine SPAC-VAX, we believe these four vaccine candidates in late-stage clinical trials have a high probability of success. In addition to our four late-stage vaccines, we continue to expand the applications of mRNA technology beyond vaccines. We should have important proof-of-concept data in patients in two of our therapeutic modalities later this year. Propionic acidemia, and methylmalonic acidemia in our rare genetic disease portfolio, and the personalized cancer vaccine. Slide 7 shows the continued growth of Moderna. We now have 46 development programs in the pipeline. The organization has continued to grow to 3,200 team members. With that, let me hand it over to Paul to review real-world evidence studies of our COVID booster. Paul?